KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Change in Cash (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Change in Cash for 16 consecutive years, with $1.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Cash rose 665.41% year-over-year to $1.0 million, compared with a TTM value of $2.1 million through Sep 2025, up 140.4%, and an annual FY2024 reading of $732000.0, up 101.63% over the prior year.
  • Change in Cash was $1.0 million for Q3 2025 at TherapeuticsMD, up from $324000.0 in the prior quarter.
  • Across five years, Change in Cash topped out at $57.1 million in Q1 2021 and bottomed at -$39.7 million in Q4 2021.
  • Average Change in Cash over 5 years is -$3.9 million, with a median of -$185000.0 recorded in 2024.
  • The sharpest move saw Change in Cash plummeted 4761.85% in 2021, then surged 6136.36% in 2025.
  • Year by year, Change in Cash stood at -$39.7 million in 2021, then soared by 127.66% to $11.0 million in 2022, then plummeted by 153.14% to -$5.8 million in 2023, then surged by 100.21% to $12000.0 in 2024, then soared by 8616.67% to $1.0 million in 2025.
  • Business Quant data shows Change in Cash for TXMD at $1.0 million in Q3 2025, $324000.0 in Q2 2025, and $686000.0 in Q1 2025.